Medrx Co

Medrx Co Equity Growth

The Year-over-Year Equity Growth of Medrx Co (4586.T) as of Nov 19, 2026 is -5.49 %. In the previous year, Year-over-Year Equity Growth was 12.74 % — a change of -143.09% (lower).

Equity Growth

-5.49 %

YoY

-143.09%

Last updated:

Year-over-Year Equity Growth of Medrx Co is 2025 -5.49 % . Year-over-Year Equity Growth of Medrx Co was 2024 12.74 % . It decreases by -143.09% lower compared to the previous year.

The Medrx Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
4.75 JPY
Jan 1, 2019
-9.85 JPY
Jan 1, 2020
11.80 JPY
Jan 1, 2021
-8.94 JPY
Jan 1, 2022
-37.98 JPY
Jan 1, 2023
58.57 JPY
Jan 1, 2024
12.74 JPY
Jan 1, 2025
-5.49 JPY
The Medrx Co Equity Growth history
YEAREquity GrowthYoY
-5.49 %-143.09%
12.74 %-78.25%
58.57 %-254.20%
-37.98 %+324.86%
-8.94 %-175.77%
11.80 %-219.85%
-9.85 %-307.44%
4.75 %-125.18%
-18.85 %+96.48%
-9.59 %-54.54%
-21.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Year-over-Year Equity Growth of Medrx Co is -5.49 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Medrx Co

All Key Metrics — Medrx Co